Skip to main content
Home > Week in Review > Other News

Chronological Index of : Other News

 Current Issue
  • J&J infectious news

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Infectious Johnson & Johnsons Janssen Pharmaceuticals Inc. unit expanded a 2012 IP policy to allow access to pediatric formulations of HIV drug Prezista …

    Published on 6/15/2015
  • Amarin cardiovascular news

    Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Business: Cardiovascular A judge in the U.S. Federal District Court for the District of Columbia granted Amarins motion for summary judgment in a suit against FDA in …

    Published on 6/8/2015
  • Amgen, Novartis biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Biosimilars The U.S. Court of Appeals for the Federal Circuit (CAFC) heard oral arguments from Amgen and …

    Published on 6/8/2015
  • Critical Path Institute, TB Alliance, St. Georges University, WHO infectious news

    Critical Path Institute, Tucson, Ariz. Global Alliance for TB Drug Development, New York, N.Y. St. Georges University, London, U.K. World Health Organization (WHO), Geneva, Switzerland Business: Infectious WHOs Special …

    Published on 6/8/2015
  • Otsuka Pharmaceutical neurology news

    Otsuka Pharmaceutical Co. Ltd., Tokyo, Japan Business: Neurology The U.S. District Court for the District of Maryland granted FDAs motion for summary judgment in a case filed by Otsuka alleging that the agency …

    Published on 6/8/2015
  • Sorrento gene/cell therapy, cancer news

    Sorrento Therapeutics Inc. (NASDAQ:SRNE), San Diego, Calif. Business: Gene/Cell Therapy, Cancer Sorrento established TNK Therapeutics Inc., a wholly owned subsidiary to develop chimeric antigen receptor tumor-attacking …

    Published on 6/8/2015
  • Acorda, Hayman Capital Management autoimmune news

    Acorda Therapeutics Inc. (NASDAQ:ACOR), Ardsley, N.Y. Hayman Capital Management, Dallas, Texas Business: Autoimmune Acorda responded to an inter partes review (IPR) filed by hedge fund manager Kyle Bass in February …

    Published on 6/1/2015
  • Astellas musculoskeletal, ophthalmic news

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Musculoskeletal, Ophthalmic Astellas released a three-year strategic plan that adds muscle disease and ophthalmology therapeutic areas. The companys innovative …

    Published on 6/1/2015
  • AstraZeneca, Eisai, Shionogi, Takeda, Drugs for Neglected Diseases initiative infectious news

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Drugs for Neglected …

    Published on 6/1/2015
  • Express Scripts cancer news

    Express Scripts Holding Co. (NASDAQ:ESRX), St. Louis, Mo. Business: Cancer The pharmacy benefit manager said it is in discussions with manufacturers about indication-based pricing for cancer drugs. Under the model, a …

    Published on 6/1/2015
  • Retrophin, Sanofi gastrointestinal news

    Retrophin Inc. (NASDAQ:RTRX), New York, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Gastrointestinal Retrophin sold its rare pediatric disease Priority Review voucher to Sanofi for $245 million. …

    Published on 6/1/2015
  • Takeda endocrine/metabolic news

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Endocrine/Metabolic Takeda agreed to pay $2.4 billion to settle all pending lawsuits filed by individuals who claimed to have been diagnosed with …

    Published on 6/1/2015
  • Teva neurology news

    Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), Petah Tikva, Israel Business: Neurology Teva will pay $1.2 billion to settle a 2008 Federal Trade Commission antitrust suit alleging that Cephalon Inc., which Teva …

    Published on 6/1/2015
  • Turnstone Biologics cancer news

    Turnstone Biologics Inc., Toronto, Ontario Business: Cancer Turnstone Biologics launched to develop and commercialize oncolytic vaccine immunotherapies using its Marabex technology to treat cancer. The technology is in …

    Published on 6/1/2015
  • AcelRx, U.S. Department of Defense neurology news

    AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX), Redwood City, Calif. U.S. Department of Defense, Washington, D.C. Business: Neurology AcelRx received a $17 million contract from the DoDs U. S. Army Medical Research and …

    Published on 5/25/2015
  • Lpath ophthalmic news

    Lpath Inc. (NASDAQ:LPTN), San Diego, Calif. Business: Ophthalmic Lpath said it will restructure and reduce its headcount by 11 (42%) to 15 after the companys iSONEP sphingomab failed in the Phase II Nexus trial to treat…

    Published on 5/25/2015
  • Redx Pharma autoimmune news

    Redx Pharma Ltd., Liverpool, U.K. Business: Autoimmune Redx launched its Redx Immunology Ltd. (Alderly Park, U.K.) subsidiary to develop drugs to treat immune system disorders. The subsidiary is aiming to identify eight…

    Published on 5/25/2015
  • Amarin cardiovascular news

    Amarin Corp. plc (NASDAQ:AMRN), Dublin, Ireland Business: Cardiovascular Amarin filed a lawsuit in the U.S. District Court for the Southern District of New York against FDA seeking a judicial declaration that the …

    Published on 5/18/2015
  • Amgen, Novartis biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Biosimilars Novartis Sandoz Inc. generics unit filed a statement with the U.S. Court of Appeals for the …

    Published on 5/18/2015
  • Calchan neurology news

    Calchan Ltd., London, U.K. Business: Neurology Calchan transitioned from a virtual company and added Brenda Reynolds as CEO, Manjit Rahelu as COO and Zahid Ali as CSO. Reynolds and Rahelu had been with Convergence …

    Published on 5/18/2015
  • Celgene, Hayman Capital Management cancer news

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Hayman Capital Management, Dallas, Texas Business: Cancer Hedge fund manager Kyle Bass filed a second inter partes review (IPR) challenging a patent covering Celgenes Revlimid …

    Published on 5/18/2015
  • Elpidera, Moderna Therapeutics chemistry news

    Elpidera LLC, Cambridge, Mass. Moderna Therapeutics Inc., Cambridge, Mass. Business: Chemistry Moderna launched Elpidera to develop mRNA-based treatments for rare diseases. Greg Licholai, formerly SVP for real-world and…

    Published on 5/18/2015
  • Quest Diagnostics, Institut National de la Sante et de la Recherche Medicale cancer news

    Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Institut National de la Sante et de la Recherche Medicale (INSERM), Paris, France Business: Cancer Quest and INSERM partnered to launch BRCA Share, a datashare …

    Published on 5/18/2015
  • Amgen, Novartis biosimilars news

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Business: Biosimilars The U.S. Court of Appeals for the Federal Circuit (CAFC) granted Amgens motion for a preliminary…

    Published on 5/11/2015
  • Beijing Jialin, Pfizer cardiovascular news

    Beijing Jialin Pharmaceutical Co. Ltd., Beijing, China Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Cardiovascular Chinas Supreme Peoples Court ruled invalid a patent covering crystalline formulations of Pfizers …

    Published on 5/11/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993